PMC3180486_01
(A) Before bevacizumab treatment, the color fundus photograph shows optic disc swelling, peripapillary hemorrhage, retinal exudates and microangiopathy. (B) Fluorescein angiography demonstrates optic disc and macular edema, capillary nonperfusion, and microaneurysms. (C) Optical coherence tomography (OCT) reveals serous retinal detachment.
opth-5-1217f1.jpg
PMC3180486_01_opth-5-1217f1.jpg
f1-opth-5-1217
OD and 0.4 OS. Ophthalmoscopy was normal in the right eye but showed optic disc swelling with peripapillary hemorrhage, retinal exudates, and intraretinal microangiopathy in the left eye (Figure 1A). The corresponding fluorescein angiogram (FA) revealed optic disc and macular edema, capillary nonperfusion, microaneurysms, and vascular leakage (Figure 1B). Optic coherence tomography (OCT) demonstrated serous retinal detachment (SRD) (Figure 1C).
(A) Two months after treatment with intravitreal bevacizumab, the color fundus photograph shows a decrease of optic disc swelling, peripapillary hemorrhage, retinal exudates and microangiopathy. (B) Fluorescein angiography demonstrates improvement of optic disc and macular edema, and microaneurysms. (C) Optical coherence tomography (OCT) reveals complete resolution of serous retinal detachment.
opth-5-1217f2.jpg
PMC3180486_01_opth-5-1217f2.jpg
f2-opth-5-1217
Two months after administration, a color photograph showed decreased optic disc swelling, hemorrhage, and exudates (Figure 2A). OCT demonstrated complete regression of SRD (Figure 2C). The corresponding FA revealed markedly reduced macular edema, decreased intraretinal microangiopathy, and vascular leakage (Figure 2B).
(A) Twelve months after treatment, the color fundus photograph shows a well-defined optic disc margin with resolution of peripapillary hemorrhage. (B) Fluorescein angiography demonstrates persistent decreased microangiopathy and vascular leakage. (C) Optical coherence tomography (OCT) reveals sustained resolution of serous retinal detachment.
opth-5-1217f3.jpg
PMC3180486_01_opth-5-1217f3.jpg
f3-opth-5-1217
These findings were maintained over 12 months and at the last follow-up (Figure 3A-C).